



Patrick Veit-Haibach

Contact

Patrick Veit-Haibach

Publications (9)

Riesterer O, Pruschy M, Bender S, Sharma A, Bogowicz M, Tanadini-Lang S, Stieb S, Bertogg K, Weber S, Ikenberg K, Huber G, Schmid S, Bredell M, Veit-Haibach P, Rordorf T, Held U, Glanzmann C, Studer G. Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study. *Radiother Oncol* 2020; 150:62–69.

de Galiza Barbosa F, Stolzmann P, Huellner M, Huber G, Pruschy M, Studer G, Stieb S, Tanadini-Lang S, Riesterer O, Veit-Haibach P. Evaluation of 18F-FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and neck squamous cell carcinoma. *Head & neck* 2019; 42:163–170.

Schneider P, Eshmunov D, Rordorf T, Vetter D, Veit-Haibach P, Weber A, Bauerfeind P, Samaras P, Lehmann K. FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study. *BMC cancer* 2018; 18:548.

Sekine T, Veit-Haibach P, von Schulthess G, Kollias S, Huber G, Ter Voert E, Stolzmann P, Burger I, Delso G, Barbosa F, Huellner M. Local resectability assessment of head and neck cancer: Positron emission tomography/MRI versus positron emission tomography/CT. *Head & neck* 2017; 39:1550–1558.

Sekine T, Veit-Haibach P, von Schulthess G, Kollias S, Huber G, Stolzmann P, Burger I, Kuhn F, de Galiza Barbosa F, Huellner M. PET+MR versus PET/CT in the initial staging of head and neck cancer, using a trimodality PET/CT+MR system. *Clin Imaging* 2017; 42:232–239.

Pietsch C, de Galiza Barbosa F, Hüllner M, Schmid D, Haerle S, Huber G, Studer G, Hany T, Veit-Haibach P. Combined PET/CT-perfusion in patients with head and neck cancers might predict failure after radio-chemotherapy: a proof of concept study. *BMC Med Imaging* 2015; 15:60.

Meerwein C, Queiroz M, Kollias S, Hüllner M, Veit-Haibach P, Huber G. Post-treatment surveillance of head and neck cancer: pitfalls in the interpretation of FDG PET-CT/MRI. *Swiss Med Wkly* 2015; 145:w14116.

Kuhn F, Hüllner M, Mader C, Kastrinidis N, Huber G, von Schulthess G, Kollias S, Veit-Haibach P. Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed?. *J Nucl Med* 2014; 55:551–8.

Strobel K, Haerle S, Stöckli S, Schrank M, Soyka J, Veit-Haibach P, Hany T. Head and neck squamous cell carcinoma (HNSCC)--detection of synchronous primaries with (18)F-FDG-PET/CT. *European journal of nuclear medicine and molecular imaging* 2009; 36:919–27.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch